Processa Pharmaceuticals, Inc. Common
PCSAProcessa Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products for serious and unmet medical conditions. The company emphasizes innovative drug development, often targeting niche markets with unmet needs, leveraging its expertise in formulation and clinical development processes.
Company News
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.
Processa Pharmaceuticals announced the acceptance of three abstracts for the 2025 ASCO Annual Meeting, highlighting its pipeline of Next Generation Cancer (NGC) drug candidates, including PCS6422 (NGC-Cap) and PCS11T (NGC-Iri).
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced its participation in the 2025 BIO CEO & Investor Conference, where it will present a corporate overview and hold one-on-one meetings with investors.
Processa Pharmaceuticals, a clinical-stage pharmaceutical company, announced the closing of a $5 million public offering. The offering included the sale of common stock and warrants to institutional investors and company insiders.
